27838809|t|Prostate and Colorectal Cancer Screening Uptake among US and Foreign-Born Males: Evidence from the 2015 NHIS Survey
27838809|a|Research suggests that prostate and colorectal cancers disproportionately affect men in the US, but little is known about the determinants of prostate-specific antigen (PSA) and colorectal cancer (CRC) screening uptake among US and foreign-born males. The purpose of this study was to investigate what factors influence prostate and colorectal cancer screening uptake among US-native born and foreign-born men. Using the 2015 National Health Interview Survey, we conducted bivariate and multivariate analyses to highlight factors associated with the uptake of prostate and colorectal cancer screening among US-native born and foreign-born men. The sample size consisted of 5651 men respondents, with the mean age of 59.7 years (SD = 12.1). Of these, more than two-fifths (42%) were aged 50-64 years old. With respect to race / ethnicity, the sample was predominantly non-Hispanic Whites (65.5%), 863 (15.6%) Hispanics, and 710 (12.4%) Blacks. Our analysis found higher rates of both US-born and foreign-born men aged 65 years or older, who had either a PSA or CRC screening tests than those aged <65 years. Results of the general multivariate model suggest that men under 50 years old, US-born and foreign-born alike, are statistically significantly less likely to have prostate or colorectal cancer screenings than men aged 65 years or above. This study highlights the influencing factors that encourage or discourage PSA and CRC screening uptake between US-native born and foreign-born men. The results of this inquiry provide an evidence -based blueprint for policymakers and interventionists seeking to address prostate and colorectal cancer among men.
27838809	0	8	Prostate	T038	UMLS:C0376358
27838809	13	30	Colorectal Cancer	T038	UMLS:C1527249
27838809	31	40	Screening	T058	UMLS:C1710032
27838809	54	56	US	T082	UMLS:C0041703
27838809	61	73	Foreign-Born	T098	UMLS:C1955874
27838809	74	79	Males	T098	UMLS:C0025266
27838809	104	108	NHIS	T170	UMLS:C1513894
27838809	109	115	Survey	T170	UMLS:C0038951
27838809	116	124	Research	T062	UMLS:C0035168
27838809	139	147	prostate	T038	UMLS:C0376358
27838809	152	170	colorectal cancers	T038	UMLS:C1527249
27838809	197	200	men	T098	UMLS:C0025266
27838809	208	210	US	T082	UMLS:C0041703
27838809	242	254	determinants	T103	UMLS:C0003316
27838809	258	283	prostate-specific antigen	T103	UMLS:C0138741
27838809	285	288	PSA	T103	UMLS:C0138741
27838809	294	311	colorectal cancer	T038	UMLS:C1527249
27838809	313	316	CRC	T038	UMLS:C1527249
27838809	318	327	screening	T058	UMLS:C1710032
27838809	341	343	US	T098	UMLS:C0079891
27838809	348	360	foreign-born	T098	UMLS:C1955874
27838809	361	366	males	T098	UMLS:C0025266
27838809	388	393	study	T062	UMLS:C2603343
27838809	436	444	prostate	T038	UMLS:C0376358
27838809	449	466	colorectal cancer	T038	UMLS:C1527249
27838809	467	476	screening	T058	UMLS:C1710032
27838809	490	504	US-native born	T098	UMLS:C0079891
27838809	509	521	foreign-born	T098	UMLS:C1955874
27838809	522	525	men	T098	UMLS:C0025266
27838809	542	574	National Health Interview Survey	T170	UMLS:C1513894
27838809	676	684	prostate	T038	UMLS:C0376358
27838809	689	706	colorectal cancer	T038	UMLS:C1527249
27838809	707	716	screening	T058	UMLS:C1710032
27838809	723	737	US-native born	T098	UMLS:C0079891
27838809	742	754	foreign-born	T098	UMLS:C1955874
27838809	755	758	men	T098	UMLS:C0025266
27838809	794	797	men	T098	UMLS:C0025266
27838809	798	809	respondents	T098	UMLS:C0282122
27838809	820	842	mean age of 59.7 years	T033	UMLS:C0243095
27838809	936	940	race	T098	UMLS:C0034510
27838809	943	952	ethnicity	T098	UMLS:C0015031
27838809	983	995	non-Hispanic	T098	UMLS:C1518424
27838809	1024	1033	Hispanics	T098	UMLS:C0019576
27838809	1051	1057	Blacks	T098	UMLS:C0085756
27838809	1063	1071	analysis	T062	UMLS:C0936012
27838809	1099	1106	US-born	T098	UMLS:C0079891
27838809	1111	1123	foreign-born	T098	UMLS:C1955874
27838809	1124	1127	men	T098	UMLS:C0025266
27838809	1169	1172	PSA	T103	UMLS:C0138741
27838809	1176	1179	CRC	T038	UMLS:C1527249
27838809	1180	1195	screening tests	T058	UMLS:C0871311
27838809	1278	1281	men	T098	UMLS:C0025266
27838809	1302	1309	US-born	T098	UMLS:C0079891
27838809	1314	1326	foreign-born	T098	UMLS:C1955874
27838809	1386	1394	prostate	T038	UMLS:C0376358
27838809	1398	1415	colorectal cancer	T038	UMLS:C1527249
27838809	1416	1426	screenings	T058	UMLS:C1710032
27838809	1432	1435	men	T098	UMLS:C0025266
27838809	1465	1470	study	T062	UMLS:C2603343
27838809	1535	1538	PSA	T103	UMLS:C0138741
27838809	1543	1546	CRC	T038	UMLS:C1527249
27838809	1547	1556	screening	T058	UMLS:C1710032
27838809	1572	1586	US-native born	T098	UMLS:C0079891
27838809	1591	1603	foreign-born	T098	UMLS:C1955874
27838809	1604	1607	men	T098	UMLS:C0025266
27838809	1629	1636	inquiry	T062	UMLS:C0035168
27838809	1678	1690	policymakers	T097	UMLS:C0242170
27838809	1695	1711	interventionists	T097	UMLS:C0027363
27838809	1723	1730	address	T170	UMLS:C0376649
27838809	1731	1739	prostate	T038	UMLS:C0376358
27838809	1744	1761	colorectal cancer	T038	UMLS:C1527249
27838809	1768	1771	men	T098	UMLS:C0025266